MedCana trades publicly as $SFWJ on OTC Markets. This page collects the materials a serious investor needs: holding structure, market thesis, strategic objectives, and the operational ramp.
A share of $SFWJ is a share of the entire MedCana stack: ten operating companies across three jurisdictions, all contributing to one vertically integrated pharmaceutical-cannabis supply chain.
Organic Leaves · Remedium · Vital Cannabis · Cannahealth Business · Cannabicolombian Group · Royal Cannabis de Colombia · Elemental Genetics
Agrotech — greenhouses, irrigation, environmental controls, monitoring
ColCanna Flower Company Ltd — Australian import & distribution licenses; the holding’s entry point to the APAC market
Planned ERP for internal use; SaaS licensing to other cannabis companies envisioned as a later phase
MedCana is preparing its first pharmaceutical-flower shipment to Australia — in process as of June 4, 2026 — and has twice delivered CBD to Switzerland, indirectly through a Colombian partner. It grows in Colombia, where pharmaceutical flower is legal and domestic sales clearance is pending, is preparing to export its next CBD crop to the Czech Republic, and has customers waiting in the UK and Germany — with Brazil tracked as a major future market.
MedCana is preparing its first shipment of pharmaceutical-grade flower to Australia, in process as of June 4, 2026. The country's legal cannabis market was estimated at $123.9M in 2024 and is expected to reach $186.4M in 2025, compounding at 23.7% CAGR through 2030. We participate directly through our Australian subsidiary, ColCanna Flower Company Ltd, which holds the import and distribution licenses.
$186M2025 market size estimateMedCana CBD has been delivered to Switzerland twice, indirectly — sold in Colombia to a partner company that exported it. The company is now preparing to export its next CBD crop directly to the Czech Republic, converting an existing trade relationship into a direct revenue channel.
CBDDelivered — moving to direct supplyPharmaceutical-grade cannabis flower is legal in Colombia, where MedCana grows. The company is awaiting the final regulatory clearance required to begin selling flower domestically — turning the operation's home country into a direct revenue market alongside export.
PendingRegulatory clearance to sell flowerThe European medical cannabis market was valued at $2.6B in 2024 and is projected to reach $12.7B by 2033. MedCana has customers waiting in the United Kingdom and Germany for THC product. In the Czech Republic, long-term supply contracts are being finalized, and MedCana is preparing to export its next CBD crop there directly.
$12.7BProjected 2033 market sizeThis is the opportunity that could reshape MedCana's scale. Recreational cannabis is already legal in Brazil — and the country is now expected to build its regulatory framework around pharmaceutical-grade standards. For a producer already cultivating to that grade, that is decisive: it means MedCana would meet the bar a national market is built on. With an estimated 360 tonnes of monthly consumption, Brazil is the single largest opportunity on MedCana's horizon — and the company is positioning now to enter the moment the framework opens.
360 tEst. monthly consumption · framework pendingEurope's largest market. The 2024 Cannabis Act opened prescribing and brought statutory health-insurance reimbursement. MedCana has customers waiting for THC product.
Medical cannabis legal on prescription since 2018, served by a substantial private-sector market. MedCana has customers waiting for THC product.
Medical cannabis legalized in 2017; one of Central Europe's larger medical markets by patient volume.
Long-term supply contracts are being finalized; MedCana is preparing to export its next CBD crop to the Czech Republic directly.
A national medical-cannabis framework is in development — a market we are monitoring closely as it formalizes.
MedCana CBD has been delivered to Switzerland twice, indirectly through a Colombian partner — with the next crop moving to direct supply.
Over a dozen European countries now run medical-cannabis programmes, with the medical segment projected at €2–4B by 2028.
Three priorities, in order. Everything else is sequencing.
Scale the Antioquia site to a 10-hectare (25-acre) build of pharmaceutical-grade greenhouses, complete GACP-aligned certification, and bring the seven licensed operators into a single coordinated production schedule. This is the bedrock — everything else depends on it shipping audit-grade product reliably.
Convert our positioning across Australia and the European medical markets into actual offtake contracts. Develop the Tokan ERP as a later phase, with SaaS licensing as a future wedge — selling SaaS subscriptions to other cannabis producers who need traceability, then convert them into distribution partners.
Community impact and environmental stewardship matter to regulators, hospitals, and institutional investors. Our farm sits in a community we employ, watered by springs we protect, audited by a software stack we wrote. This is not a marketing posture — it's how the operation already runs.
Recreational and pharmaceutical cannabis look superficially similar and trade at very different prices. What separates them is documentation: consistent cannabinoid profiles, validated terpene panels, heavy-metal and pesticide screens, full batch traceability, and licensed production conditions.
Hospitals, importers, and pharmacies across Germany, the UK, and Australia will not buy from producers who can't deliver that documentation. The cost of producing it is non-trivial, which is why most cannabis companies don't — and why the companies that do command meaningfully higher prices.
MedCana's strategy is to be one of the small number of companies on the supply side of that equation.
The current sales presentation — including detailed market analysis, the strategic build-out plan, and management backgrounds — is available to qualified institutional investors on request.
We publish operational milestones, harvest updates, and certification progress regularly. Add your email and we'll send the next update direct.
